期刊文献+

聚天冬氨酸-酪氨酸纳米胶束载体的制备及载药性能研究

Study on preparation and drug loading property of polyaspartic acid-tyrosine nano micelle carrier
下载PDF
导出
摘要 聚天冬氨酸接枝酪氨酸可形成具有较强载药能力的自组装纳米胶束载体,以此为研究对象探讨了碳二亚胺盐酸盐/N-羟基琥珀酰亚胺(EDC/NHS)催化体系对酰胺化反应的影响以及疏水段酪氨酸接枝率对胶束载体载药率的影响。结果表明,EDC/NHS催化体系比例的增加会提高反应的接枝率,而疏水段酪氨酸接枝率的增加可以提高对疏水性药物的负载能力,接枝率从0升高到26%的过程中可以使载药率从4.0%提高至58.16%。利用具有肿瘤靶向性能的叶酸对载体进行化学修饰得到兼具pH响应性和体内主动靶向能力的多重响应性高载药率纳米胶束载体。 Graft of tyrosine onto polyaspartic acid formed self-assembled micelle carriers with strong drug loading ability.The effect of EDC/NHS catalytic system on amidation reaction and the effect of tyrosine grafting rate on drug loading rate were investigated.Finally,it was concluded that under certain conditions,the increase of EDC/NHS usage increased the graft rate of the reaction,while the increase of tyrosine graft rate of hydrophobic segment improved the loading capacity of hydrophobic drugs,and the drug loading rate increased from 4.0%to 58.16%when the graft rate increased from 0 to 26%.In addition,folic acid,a recognized target ligand,was used to chemically modify the carrier with the aim to obtain multiple responsive nano micellar carriers with high drug loading,evident pH responsiveness and in vivo active targeting ability.
作者 李天杨 李强 付东升 侯文娟 张杰 郭睿劼 Li Tianyang;Li Qiang;Fu Dongsheng;Hou Wenjuan;Zhang Jie;Guo Ruijie(College of Materials Science and Engineering,Taiyuan University of Technology,Taiyuan 030024)
出处 《化工新型材料》 CAS CSCD 北大核心 2021年第6期179-183,共5页 New Chemical Materials
基金 山西省自然科学基金(201701D121030,201701D121044,201901D211091)。
关键词 聚天冬氨酸 酪氨酸 接枝率 载药率 叶酸 主动靶向 polyaspartic acid tyrosine graft rate drug loading rate folic acid active targeting
  • 相关文献

参考文献7

二级参考文献60

  • 1杜春燕,师英强,傅红,赵广法,周烨,蔡国响.胃肠道间质瘤103例预后分析[J].中国实用外科杂志,2007,27(4):297-299. 被引量:49
  • 2徐铮奎.国外大力开发氨基酸新用途 [J].中国化工报,2001,.
  • 3向智敏.天然食品保鲜剂-聚赖氨酸 .广州食品工业科技,1993,.
  • 4Coiffier B. Rituximab therapy in malignant lymphoma [J ]. Oncogene, 2007,26(25):3603-3613.
  • 5Jonker DJ, O'Callaghan C J, Karapetis CS, et al. Cetuximab for the treatment of eolorectal cancer [J]. N Engl J Med, 2007,357 (20):2040-2048.
  • 6Amado RG, Wolf M, Peeters M, et al. Wild-type k-ras is required for panitumumab efficacy in patients with metastatic colorectal cancer[J ]. J Clin Oncol, 2008,26(10): 1626-1634.
  • 7Untch M, Muscholl M, Tjulandin S, et al. First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the herceptin, cyclophosphamide, and epirubicin (HERCULES) trial [J]. J Clin Oncol, 2010,28(9):1473-1480.
  • 8Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer[J]. N Engl J Med, 2004,350(23):2335-2342.
  • 9Heinrich MC, Owzar K, Corless CL, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 study by Cancer and Leukemia Group B and Southwest Oncology Group [J]. J Clin Oncol, 2008,26(33):5360-5367.
  • 10Wu Y, Mok T, Chu D, et al. Evaluation of clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) recruited in China in a phase Ill, randomized, open-label, first-line study in Asia of gefitinib (G) versus carboplatin/paclitaxel (C/P)(IPASS)[J]. ASCO meeting abstracts, 2009,27(15S): 8041.

共引文献167

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部